First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve

被引:154
|
作者
Rodriguez-Grunert, Leonardo [1 ]
Neto, Manoel Passos Galvao [2 ]
Alamo, Munir [1 ]
Ramos, Almino Cardoso [2 ]
Baez, Percy Brante [1 ]
Tarnoff, Michael [3 ]
机构
[1] Hosp Dipreca, Ctr Cirugia Obesidad, Santiago, Chile
[2] Gastro Obeso Ctr, Sao Paulo, Brazil
[3] Tufts Univ New England Med Ctr, Dept Surg, Boston, MA USA
关键词
Bariatric; Endoluminal; Diabetes; Obesity; Duodenum;
D O I
10.1016/j.soard.2007.07.012
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: We report the first human experience with an endoscopic duodenal-jejunal bypass sleeve (DJBS) in a community hospital. Methods: The DJBS is a 60-cm sleeve anchored in the duodenum to create a duodenal-jejunal bypass. In a 12-patient prospective, open-label, single-center, 12-week study, the device was endoscopically implanted, left in situ, and retrieved. The study included 5 men and 7 women, with a mean body mass index of 43 kg/m(2). Of the 12 patients, 4 had type 2 diabetes. The primary endpoints were the incidence and severity of adverse events. The secondary outcomes included the percentage of excess weight loss and changes in co-morbid status. Results: The DJBS was endoscopically delivered and retrieved in all patients (mean implant/explant time of 26.6 and 43.3 min, respectively). Of the 12 patients, 10 were able to maintain the device for 12 weeks and 2 underwent explantation after 9 days secondary to poor device placement. Several self-limited adverse events were possibly or definitely related to the device, including 6 episodes of abdominal pain, 18 of nausea, and 16 of vomiting, mainly within 2 weeks of implantation. Two partial pharyngeal tears occurred during explantation. Implant site inflammation was encountered in all patients. No device-related event was considered severe. The average percentage of excess weight loss for the 10 patients with the device in place for 12 weeks was 23.6%, with all patients achieving at least 10% excess weight loss. All 4 diabetic patients had normal fasting plasma glucose levels without hypoglycemic medication for the entire 12 weeks. Of these 4 patients, 3 had decreased hemoglobin A(1C) of >=.5% by week 12. Conclusion: The DJBS can be safely delivered and removed endoscopically and left in situ for 12 weeks. The device had a favorable safety and encouraging efficacy profile. Randomized prospective trials are warranted. (Surg Obes Relat Dis 2008;4:55-59.) (C) 2008 American Society for Metabolic and Bariatric Surgery. All rights reserved.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 50 条
  • [41] Effect of duodenal-jejunal bypass on diabetes in the early postoperative period
    Shohei Okikawa
    Hideya Kashihara
    Mitsuo Shimada
    Kozo Yoshikawa
    Takuya Tokunaga
    Masaaki Nishi
    Chie Takasu
    Yuma Wada
    Toshiaki Yoshimoto
    Scientific Reports, 13
  • [42] Effect of duodenal-jejunal bypass on diabetes in the early postoperative period
    Okikawa, Shohei
    Kashihara, Hideya
    Shimada, Mitsuo
    Yoshikawa, Kozo
    Tokunaga, Takuya
    Nishi, Masaaki
    Takasu, Chie
    Wada, Yuma
    Yoshimoto, Toshiaki
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [43] IS RE-IMPLANTATION OF THE DUODENAL-JEJUNAL BYPASS LINER VIABLE?
    Guenthert, Sarah
    Dienethal, Antje
    Stein, Jurgen
    GASTROENTEROLOGY, 2017, 152 (05) : S135 - S135
  • [44] Adverse Events of the Duodenal-Jejunal Bypass Liner: a Systematic Review
    Bark Betzel
    Joost P. H. Drenth
    Peter D. Siersema
    Obesity Surgery, 2018, 28 : 3669 - 3677
  • [45] The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss
    Ruban, Aruchuna
    Ashrafian, Hutan
    Teare, Julian P.
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2018, 2018
  • [46] Is Re-implantation of the Duodenal-Jejunal Bypass Liner Feasible?
    Betzel, B.
    Koehestanie, P.
    Dogan, K.
    Aarts, E.
    Janssen, I.
    Groenen, M.
    Wahab, P.
    de Boer, H.
    van Laarhoven, C.
    Berends, F.
    OBESITY SURGERY, 2013, 23 (08) : 1037 - 1038
  • [47] Adverse Events of the Duodenal-Jejunal Bypass Liner: a Systematic Review
    Betzel, Bark
    Drenth, Joost P. H.
    Siersema, Peter D.
    OBESITY SURGERY, 2018, 28 (11) : 3669 - 3677
  • [48] Endoscopic Treatment of Obesity With a Duodenal-Jejunal Bypass Sleeve: Does Impairment of Fat Absorption Explain Weight Loss?
    Rich, Graeme
    McMaster, Jessica
    von Wulffen, Moritz T.
    Gandhi, Arjun
    Fletcher, Linda
    Gupta, Saurabh
    Russell, Anthony
    Chikani, Viral
    Veronique, Chachay
    Holtmann, Gerald
    GASTROENTEROLOGY, 2016, 150 (04) : S604 - S604
  • [49] Type 2 Diabetes Control in a Nonobese Rat Model Using Sleeve Gastrectomy with Duodenal-Jejunal Bypass (SGDJB)
    Sun, Dong
    Liu, Shaozhuang
    Zhang, Guangyong
    Chen, Weijie
    Yan, Zhibo
    Hu, Sanyuan
    OBESITY SURGERY, 2012, 22 (12) : 1865 - 1873
  • [50] Clinical Experience With a Second Generation, 6 Month Duration, Endoscopic, Duodenal-Jejunal Bypass Liner
    Escalona, Alex
    Anrique, Luis I.
    Pimentel, Frenando
    Sharp, Allan C.
    Galvao, Manoel
    Gersin, Keith S.
    GASTROINTESTINAL ENDOSCOPY, 2010, 71 (05) : AB200 - AB201